Short answer
Enliven Therapeutics, Inc. (ELVN) filed an 8-K current report with the SEC on June 10, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws). Stockholders elected Richard Fair and Lori Kunkel as Class III directors through the 2029 annual meeting.
Enliven Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Stockholders elected Richard Fair and Lori Kunkel as Class III directors through the 2029 annual meeting
- Authorized common shares doubled from 100,000,000 to 200,000,000, increasing capacity for financings, acquisitions, or equity compensation
- Deloitte & Touche LLP ratified as independent auditor for fiscal year ending December 31, 2026
- Executive compensation approved on an advisory basis, with 47,572,153 votes supporting
- Annual advisory votes on executive compensation adopted, with the next frequency vote due by the 2032 annual meeting
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Enliven Therapeutics, Inc. 8-K filings
Get the next ELVN 8-K as it lands
Follow ELVN for push alerts, or ask the research agent what this filing means.